Introduction {#s1}
============

Tuberculosis (TB) continues to be the most common cause of mortality among patients infected with human immunodeficiency virus (HIV). The burden of this dual global epidemic of HIV and TB is extremely high in sub-Saharan Africa with the World Health Organization (WHO) estimating 86% of the deaths related to HIV associated TB coming from this region ([@B42]). Effective treatment for both TB and HIV diseases simultaneously poses numerous challenges because of potential interactions between antituberculosis and antiretroviral, clinical deterioration from immune reconstitution inflammatory syndrome, overlapping adverse events, and high medication burden ([@B41]).

Of importance in TB-HIV co-treatment are rifamycin derivatives, which induce the hepatic cytochrome P450 enzyme system resulting in increased metabolism and lowering serum concentrations of antiretrovirals, including efavirenz ([@B27]). Efavirenz based combination antiretroviral therapy (cART) is currently the treatment of choice for patients who are receiving rifampicin based antituberculosis co-treatment in most countries, including Ethiopia and Tanzania. As a result, there is a concern that the co-administration of rifampicin may increase the risk of virologic failure for HIV/TB patients receiving efavirenz-based regimens ([@B27]). Plasma efavirenz levels in the presence of rifampicin are highly variable between patients partly due to pharmacogenetic variations ([@B33]). Patients homozygous for the defective *CYP2B6\*6* variant allele, which is more common among African populations as compared to Caucasians, tend to experience higher levels of efavirenz when it is co-administered with rifampicin ([@B23]).

Sub-Saharan African populations display the highest level of genetic and phenotypic diversity than any other race in the world ([@B17]). Previous studies have shown higher levels of genetic diversity within black Africans compared to other non-Africans populations ([@B6]: [@B21]: [@B9]), and genetic diversity reduces with distance from East Africa ([@B39]: [@B22]). Even within East Africa populations, there is wide genetic, environmental, cultural, and linguistic diversity. For instance, Ethiopians are predominantly of Semitic and Cushitic origin while Tanzanians comprise predominantly of Bantu and Nilotic origins. Apart from genetic and environmental factors, nutrition, geographical and population variation, and the use of traditional medicine may also contribute to between-patient and population variation, which may alter the extent of drug metabolism, efficacy, and adverse event profiles ([@B1]: [@B12]: [@B20]). For instance, the prevalence of efavirenz-based cART-associated liver and CNS toxicity profiles varies significantly between Ethiopians and Tanzanians ([@B43]: [@B44]: [@B28]: [@B29]).

The role of between population variations for efavirenz pharmacokinetics, auto-induction, and the immunological outcome is well investigated ([@B40]: [@B37]). However, its impact during concomitant anti-tuberculosis regimen known to induce/inhibit the metabolism and cellular transport of antiretrovirals is not well understood. There are conflicting reports on the impact of pharmacogenetic diversity and population differences on the interaction between efavirenz and rifampicin from different populations, with some reporting decreased efavirenz plasma exposure by concomitant rifampicin co-treatment whereas others report no effect or increased plasma efavirenz concentration ([@B24]: [@B15]: [@B16]: [@B19]).

Given the high genetic diversity and prevalence of TB-HIV coinfection in Sub-Saharan Africa, it is important to investigate the role of population differences including environmental and cultural diversity on antiretroviral and anti-TB drug interaction and the resulting impact on the treatment outcomes including safety and efficacy. Characterization of pharmacogenetics, pharmacokinetics, enzyme induction, and treatment outcomes between different African populations would form a base for personalized medicine and population-specific rationalized efavirenz dose adjustment strategies during anti-TB co-treatment in Africa. This study aimed at evaluating the impact of population and pharmacogenetic variation for efavirenz-rifampicin interaction, efavirenz pharmacokinetics, and immunologic outcome in Tanzanians and Ethiopians---the two east African populations that display wide genetic, environmental, cultural, nutritional, geographical, and linguistic variations.

Patients and Methods {#s2}
====================

Study Population and Setting {#s2_1}
----------------------------

This study is part of a larger prospective cohort study funded by European and Developing Countries Clinical Trial Partnership (EDCTP) titled "Optimization of tuberculosis and HIV co-treatment in Africa: Pharmacokinetic and pharmacogenetic aspects on drug-drug interactions between rifampicin and efavirenz." The study design, population eligibility criterions were described previously ([@B28]: [@B19]). In brief newly diagnosed TB patients with HIV co-infection who fulfilled inclusion criteria of age ≥18 years, CD~4~ count \<200 cells/µl, naïve to cART were recruited and enrolled. Patients were started with a fixed drug combination consisting of rifampicin, isoniazid, ethambutol, and pyrazinamide for 2 months of intensive phase, followed by a continuation phase of 4 months with rifampicin and isoniazid for a total duration of 6 months. After 4 weeks of anti-TB treatment, cART was initiated with 2 nucleoside reverse-transcriptase inhibitors (NRTI) \[either stavudine/lamivudine (d4T/3TC), zidovudine/lamivudine (AZT/3TC), or tenofovir/lamivudine (TDF/3TC)\] and efavirenz and the patients were followed up to 1 year to monitor the immunological outcome. A parallel cohort of ART naïve HIV-only patients (209 Tanzanian and 285 Ethiopian) were enrolled as a control group and initiated efavirenz-based cART only and followed up for the same duration of time ([@B37]).

The study received ethical approval from Institutional Review Board (IRB) of the Muhimbili University of Health and Allied Sciences in Dar es Salaam, Tanzania, by the IRB of Faculty of Medicine, Addis Ababa University, and Ethiopian National Ethics Review Committee and by the IRB of Karolinska Institutet in Stockholm, Sweden. Prior written informed consent was obtained from all study participants.

Clinical and Laboratory Parameters {#s2_2}
----------------------------------

At enrollment baseline, clinical and laboratory parameters were assessed. Pretreatment laboratory tests included complete and differential blood counts, hemoglobin, platelet count, CD~4~ cell count, HIV RNA determination, hepatitis B surface antigen, anti-hepatitis C antibody, serum albumin, renal function tests, and liver enzymes including serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and direct and total bilirubin levels. Change in CD~4~ count from baseline was monitored at 12^th^, 24^th^, and 48^th^ weeks of ART in both TB-HIV and HIV only cohorts.

Efavirenz Plasma Concentration Determination {#s2_3}
--------------------------------------------

At 4 and 16 weeks of initiating efavirenz-based cART, a 16-h post-efavirenz dose blood samples were collected in vacutainer Cell Preparation Tubes (CPT) tubes (Becton Dickinson, Heidelberg, Germany). Blood samples were centrifuged (1,700 g for 20 min) to prepare plasma and stored at −80°C. Plasma efavirenz concentrations were quantified by liquid chromatography-tandem mass spectrometry (LC/MS/MS) as described previously ([@B36]). Efavirenz was quantified using ^13^C~6~-efavirenz as internal standards where the lower limits of quantification were 0.01 µg/ml. The efavirenz calibration range was 0.01--10 µg/ml. Linear regression with 1/x weighing resulted in correlation coefficients of r^2^ 0.99. Accuracy and precision (within-batch and batch-to-batch) of the assay fulfilled all recommendations of FDA guidelines.

Genotyping for *CYP2B6*, *CYP3A5*, *ABCB1*, *SLCO1B1*, and *UGT2B7* {#s2_4}
-------------------------------------------------------------------

Genomic DNA was isolated from peripheral blood leukocytes using QIAamp DNA Maxi Kit (QIAGEN GmbH, Hilden, Germany). Genotyping for the common functional variant alleles in five relevant genes for efavirenz disposition were done using allelic discrimination TaqMan genotyping assays (Applied Biosystems, CA, USA) with the following ID number for each single nucleotide polymorphisms (SNP): (C:7586657_20 for *ABCB1 c.3435C \> T* rs1045642, C:11711730_20 for *CYP2B6\*6 c.516G \> T* rs3745274, C:30720663_20 for UGT2B7 g.-327G \> A rs7662029 (*UGT2B7\*2*), C:26201809_30 for *CYP3A5\*3* c.6986A \> G rs776746, C:30203950_10 for *CYP3A5\*6 14690G \> A g.14690G \> A*, C:32287188_10 for *CYP3A5\*7* g.27131_27132insT rs241303343, C:\_1901697_20 for *SLCO1B1* c.388A \> G rs2306283 (*\*1b*), and C:30633906_10 for *SLCO1B1 c.521T \> C* rs4149056 (\*5) on ABI 7500 FAST (Applied Biosystems, Foster City, CA). The final volume for each reaction was 10 μl, consisting of 2 X TaqMan Universal PCR Master Mix (Applied Biosystems), 20 X drug metabolizing genotype assay mix, and 10 ng genomic DNA. The PCR profile consisted of an initial step at 50°C for 2 min and 50 cycles with 95°C for 10 min and 92°C for 15 s. Genotyping for SLCO1B1 c.388A \> G (rs2306283) and c.521T \> C (rs4149056) in Tanzania was done using Light Cycler H based method ([@B2]; [@B3]).

Statistical Analysis {#s2_5}
--------------------

Baseline socio-demographic and laboratory parameters were described as means and standard deviations (SD) or medians and interquartile range (IQR) for continuous variables and as percentages for categorical variables. The normality of kinetic data was assured by transforming the data to log 10 values before statistical analysis. Independent t-tests were used to compare log-transformed plasma efavirenz concentration at 4 and 16 weeks after cART initiation between Tanzanian and Ethiopian patients. Predictors of efavirenz plasma concentrations were assessed using univariate and multivariate regression analysis. Linear regression models were used to estimate predictors of log efavirenz concentrations at 4 and 16 weeks, separately. Similarly, the predictors of immunological outcomes at week 48 were assessed. Log-binomial regression analysis was used to estimate the relative risk of efavirenz concentrations \<1 µg/ml at 4 and 16 weeks, separately. To take into account the repeated measure design and examine predictors of efavirenz longitudinally, we used generalized estimating equations (GEEs) with an exchangeable working covariance and identify the link to produce population-averaged mean differences in efavirenz concentrations while the log link for the population-averaged relative risk of efavirenz \<1 µg/ml. Variables in univariate analysis with a *p \<*0.2 were included in all multivariate analyses. All *p-*values were two-sided, and *p-*values of \< 0.05 were considered statistically significant. Statistical analyses were performed using Stata version 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC).

Results {#s3}
=======

Study Population and Baseline Characteristics {#s3_1}
---------------------------------------------

A total of 921 treatment naïve HIV patients with or without TB-HIV coinfection were enrolled in a multi-national parallel prospective cohort study: 427 TB-HIV co-infected patients (196 in Ethiopia and 231 in Tanzania) and 494 HIV patients without TB coinfection (285 in Ethiopia and 209 in Tanzania). The HIV only cohort treated with efavirenz-based cART only were used as a control group to examine the impact of population differences on efavirenz-rifampicin drug interaction. The sociodemographic, clinical, and laboratory, pharmacogenetic, and pharmacokinetic data of the HIV-only cohort is described previously ([@B37]).

The sociodemographic, baseline clinical, and laboratory characteristics of the TB-HIV cohort are presented in [**Table 1**](#T1){ref-type="table"}. Sputum smear microscopy for tuberculosis showed that 43.8% were smear-positive, and the remaining were diagnosed to have smear negative-pulmonary tuberculosis ([**Table 1**](#T1){ref-type="table"}). The mean (±SD) BMI of all patients was 19.2 ± 3.2 but Ethiopians had a significantly higher proportion of patients with a BMI ≤18.5 kg/m^2^ compared to the Tanzanians (49.5 *vs*. 39.3% respectively) (p = 0.03). The mean (±SD) hemoglobin was 10.6 ± 2.2 with Tanzanians (19%) having significantly more patients with a hemoglobin of \<8.5g/dl compared to the Ethiopians (10%) (p = 0.02). The patients were severely immunocompromised with a mean CD~4~ cell count of 97.7 cells/µl with over half having a CD~4~ cell count of \<100 cells/µl in both settings.

###### 

Sociodemographic and baseline clinical characteristics of Tanzanian and Ethiopian TB-HIV patients on efavirenz-based combination antiretroviral-therapy (cART) and rifampicin based anti-TB therapy.

  -------------------------------------------------------------------------------------------------------------
  Variable                                 Tanzania\                        Ethiopia\             
                                           N = 231                          N = 196               
  ---------------------------------------- -------------------------------- --------------------- -------------
  Sex                                      Males                            117 (50.6%)           103 (52.6%)

                                           Females                          114 (49.4%)           93 (47.4%)

  Median age in years (IQR)                38 (12)                          35 (13)               

  Marital status                           Single                           61 (26.4%)            69 (35.2%)

                                           Married                          116 (50.2%)           68 (34.7%)

                                           Widowed                          20 (8.7%)             27 (13.8%)

                                           Divorced                         34 (14.7%)            32 (16.3%)

  Education                                Illiterate                       9 (3.9%)              28 (14.3%)

                                           Able to read/write and primary   185 (80.1%)           88 (44.9%)

                                           Secondary and tertiary           37 (16.0%)            80 (40.8%)

  Type of TB                               Smear positive                   155 (67.1%)           32 (16.3%)

                                           Smear negative                   76 (32.9%)            164 (83.7%)

  WHO stages                               Stage III                        217 (93.9%)           130 (66.3%)

                                           Stage IV                         14 (6.1%)             66 (33.7%)

  cART                                     d4T+3TC+EFV                      116 (50.9%)           85 (45.4%)

                                           AZT+3TC+EFV                      112 (49.1%)           48 (25.7%)

                                           TDF+3TC+EFV                      0                     54 (28.9%)

  BMI (Kg/m^2^) \[median, IQR\]            19.3 \[3.7\]                     18.6 \[2.8\]          

  BMI categories                           \<18.5                           90 (39.3%)            97 (49.5%)

                                           \>18.5                           139 (60.7%)           99 (50.5%)

  Hb (g/dl) \[median, IQR\]                9.7 \[2.3\]                      11.3 \[3.2\]          

  Severe anemia (\< 8.5g/dl)               Yes                              39 (18.8%)            20 (10.2%)

                                           No                               169 (81.2%)           176 (89.8%)

  AST (IU/L) \[median, IQR\]               28.7 \[24.2\]                    43 \[37.5\]           

  ALT (IU/L) \[median, IQR\]               17 \[18.6\]                      29 \[20.5\]           

  Hepatitis B                              Negative                         163 (96.4%)           181 (92.3%)

                                           Positive                         6 (3.6%)              15 (7.7%)

  Hepatitis C                              Negative                         182 (98.9%)           191 (97.9%)

                                           Positive                         2 (1.1%)              4 (2.1%)

  CD4 (cells/µl) \[median, IQR\]           94 \[122\]                       78.5 \[87.5\]         

  CD4 categories                           \<100 cells/µl                   118 (51.1%)           113 (57.7%)

                                           100--200 cells/µl                113 (48.9%)           83 (42.3%)

  Viral load (copies/ml) \[median, IQR\]   226,000 \[542,200\]              169,758 \[330,568\]   
  -------------------------------------------------------------------------------------------------------------

WHO stage, World Health Organization clinical staging; cART, combination antiretroviral therapy; d4T, stavudine; AZT, zidovudine; TDF, tenofovir; 3TC, lamivudine; EFV, efavirenz; BMI, body mass index; Hb, hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Distribution of Allele and Genotype Frequencies in Ethiopians and Tanzanians {#s3_2}
----------------------------------------------------------------------------

Three hundred and twenty-eight TB-HIV coinfected patients had their genotype determined (145 Tanzanians and 183 Ethiopians). Comparison of *CYP2B6, CYP3A5, UGT2B7, ABCB1,* and *SLCO1B1* genotype and variant allele frequency distribution between Ethiopians and Tanzanian TB-HIV patients is presented in [**Table 2**](#T2){ref-type="table"}. Except for *CYP2B6\*6* and *CYP3A5\*6,* the distribution of all other variant alleles genotypes for were significantly different between the two study populations. Though not significant, Tanzanians had a higher allele frequency of the defective *CYP2B6\*6* variant allele than Ethiopians. Proportionately more Tanzanians had the *\*6/\*6* allele compared to the Ethiopians (58.8% compared to 41.2%). The defective variant allele *CYP3A5\*7* was absent in Ethiopians but occurred at a frequency of 10% in Tanzanians. Due to the high frequency (70%) of the defective *CYP3A5\*3* variant allele, the frequency of functional *CYP3A5\*1* allele in Ethiopians was significantly lower in Ethiopians (22.3%) than Tanzanians (50.4%). Likewise, the defective *SLCO1B1\*5* variant allele occurs at a much higher frequency in Ethiopians than Tanzanians.

###### 

Comparison of *CYP2B6*, *CYP3A5*, *UGT2B7*, *ABCB1*, and *SLCO1B1*genotype and allele frequencies distribution of functional variant alleles among TB-HIV co-infected Ethiopians and Tanzanians patients.

  Genotype                                   Ethiopia      Tanzania      p
  ------------------------------ ----------- ------------- ------------- ----------
  *CYP2B6\*6*                    *\*1/\*1*   74 (50.0%)    72 (49.7%)    0.25
                                 *\*1/\*6*   62 (41.9%)    53 (36.6%)    
                                 *\*6/\*6*   12 (8.1%)     20 (13.8%)    
  *CYP3A5\*3*                    *\*1/\*1*   28 (15.3%)    87 (60.0%)    \<0.001
                                 *\*1/\*3*   87 (47.5%)    51 (35.2%)    
                                 *\*3/\*3*   68 (37.2%)    7 (4.8%)      
  *CYP3A5\*6*                    *\*1/\*1*   127 (69.4%)   102 (70.3%)   0.85
                                 *\*1/\*6*   49 (26.8%)    36 (24.8%)    
                                 *\*6/\*6*   7 (3.8%)      7 (4.8%)      
  *CYP3A5\*7*                    *\*1/\*1*   183 (100%)    116 (80.0%)   \<0.001
                                 *\*1/\*7*   0             29 (20.0%)    
  Number of *CYP3A5\*1* allele   Zero        111 (60.7%)   41 (28.3%)    \<0.0001
                                 One         62 (33.9%)    62 (42.8%)    
                                 Two         10 (5.5%)     42 (29.0%)    
  *UGT2B7\*2*                    *AA*        45 (24.6%)    15 (10.3%)    \<0.0001
                                 *AG*        90 (49.2%)    61 (42.1%)    
                                 *GG*        48 (26.2%)    69 (47.6%)    
  *ABCB1 c.3435C \> T*           *CC*        118 (64.5%)   109 (75.2%)   0.10
                                 *CT*        54 (29.5%)    31 (21.4%)    
                                 *TT*        11 (6.0%)     5 (3.4%)      
  *ABCB1 c.4036A \> G*           *AA*        126 (68.9%)   72 (49.7%)    0.0007
                                 *AG*        53 (29.0%)    62 (42.8%)    
                                 *GG*        4 (2.2%)      11 (7.6%)     
  *SLCO1B1 D130N (\*1b)*         *AA*        24 (13.1%)    3 (2.1%)      \<0.0001
                                 *AG*        102 (55.7%)   32 (22.2%)    
                                 *GG*        57 (31.1%)    109 (75.7%)   
  *SLCO1B1 A174V (\*5)*          *TT*        112 (61.2%)   133 (92.4%)   \<0.0001
                                 *CT*        67 (36.6%)    11 (7.6%)     
                                 *CC*        4 (2.2%)      0 (0.0%)      
  **Allele frequency**                                                   
  *CYP2B6\*6*                    29.1%       32.1%         0.42          
  *CYP3A5\*3*                    60.9%       22.4%         \<0.0001      
  *CYP3A5\*6*                    17.2%       17.3%         0.99          
  *CYP3A5\*7*                    0           11.1%         \<0.0001      
  Number of *CYP3A5\*1* allele   22.4%       50.3%         \<0.0001      
  *UGT2B7\*2*                    50.8%       68.6%         \<0.0001      
  *ABCB1 c.3435C \> T*           20.8%       14.1%         0.02          
  *ABCB1 c.4036A \> G*           16.7%       30.0%         0.0001        
  *SLCO1B1 D130N (\*1b)*         59.0%       86.8%         \<0.0001      
  *SLCO1B1 A174V (\*5)*          20.0%       3.8%          \<0.0001      

Efavirenz Plasma Concentrations On and Off Rifampicin Co-Treatment {#s3_3}
------------------------------------------------------------------

Comparison of plasma efavirenz concentration between Ethiopian and Tanzanian HIV patients receiving efavirenz-based cART only (control group) *versus* TB-HIV patients co-treated with efavirenz (EFV) based cART and rifampicin based anti-TB therapy at the 4^th^ and 16^th^ week of ART is presented in [**Figure 1**](#f1){ref-type="fig"}. In the HIV only cohort, there were significant differences in efavirenz plasma concentration between the two study populations, being higher in Tanzanian than Ethiopian patients both at the 4^th^ and 16^th^ weeks of cART ([**Figure 1**](#f1){ref-type="fig"}). However, in TB-HIV patients co-treated with rifampicin based anti-TB therapy, there was no significant between-population difference in plasma efavirenz exposure observed at both study time points. Though not significant, the geometric mean (95% confidence interval) of efavirenz plasma concentration in Tanzanian TB-HIV patients was slightly lower compared to the Ethiopian patients \[1.49 (95% CI: 1.27--1.76) µg/ml and 1.66 (95% CI: 1.35--2.05) µg/ml, respectively\].

![Comparison of mean ± standard errors efavirenz plasma concentration between Ethiopian and Tanzanian patients at the 4^th^ and 16^th^ weeks of efavirenz-based *combination antiretroviral-therapy* (cART) using independent t-test.](fphar-11-00026-g001){#f1}

Comparison of plasma efavirenz concentration while on (EFV+RIF) and off (EFV-only) rifampicin co-treatment among Ethiopians and Tanzanians stratified by *CYP2B6\*6* genotype group at week 4 and 16 of cART is presented in [**Figure 2**](#f2){ref-type="fig"}. In Tanzanian patients, short term rifampicin co-treatment significantly reduced plasma efavirenz concentration (week-4 of cART), particularly in *CYP2B6\*1/\*1* genotype group (p = 0.005), but no significant effect was observed in Tanzanian *CYP2B6\*6* carriers. On the other hand, though not significant, there was a trend of having higher mean efavirenz plasma concentration among those co-treated with rifampicin than those without rifampicin in Tanzanian *CYP2B6\*6* carriers (p = 0.18) at week 16 of cART but not in *CYP2B6\*1/\*1* (p = 0.68).

![Comparison of mean log efavirenz plasma concentrations in the absence \[efavirenz (EFV) only\] and presence of rifampicin based anti-TB cotreatment \[EFV + (rifampicin) RIF\] among Ethiopian and Tanzanian HIV patients stratified by CYP2B6\*6 genotype at week 4 and week 16 of *combination antiretroviral-therapy (*cART). Bars indicate mean ± 95% confidence intervals of the mean.](fphar-11-00026-g002){#f2}

In contrast, among Ethiopian patients, anti-TB cotreatment increased the mean plasma efavirenz concentration, particularly among carriers of *CYP2B6\*6* allele both at week 4 (p = 0.003) and at week 16 (p = 0.035). Though not significant, a similar trend was observed in *CYP2B6\*1/\*1* genotype at week 4 (p = 0.18) and at week 16 (p = 0.36). Overall long-term rifampicin co-treatment increased plasma efavirenz concentration in Ethiopians being higher in *CYP2B6\*6/\*6* \> *\*1/\*6* \> *\*1/\*1* ([**Figure 2**](#f2){ref-type="fig"}).

Change in Plasma Efavirenz Concentration Overtime {#s3_4}
-------------------------------------------------

Change in plasma efavirenz concentration from week 4 to 16 of cART stratified by treatment group and study population is presented in [**Figure 3**](#f3){ref-type="fig"}. Repeated measure ANOVA indicated a significant interaction between country and treatment arm in influencing plasma efavirenz concentration over time (p = 0.006). Among HIV patients treated with efavirenz-based cART only, within-population analyses using paired samples t-test indicated a pronounced efavirenz autoinduction in Tanzanians as reflected by a significant decrease in the mean plasma efavirenz concentration at week 16 than week 4 (p = 0.0001), whereas no significant differences in plasma concentration over time were observed in Ethiopians (p = 0.14). On the other hand, no significant change in efavirenz plasma concentration between the 4^th^ and 16^th^ weeks of cART was observed in TB-HIV patients co-treated with rifampicin based anti-TB therapy regardless of country of origin ([**Figure 2**](#f2){ref-type="fig"}).

![Comparison of change in plasma efavirenz concentration from week 4 to week 16 of *combination antiretroviral-therapy* (cART) among Ethiopian and Tanzanian HIV patients treated with efavirenz based cART only \[efavirenz (EFV) only\] or co-treated with rifampicin based antituberculosis therapy \[EFV + rifampicin (RIF)\]. Bars indicate mean ± 95% confidence intervals of the mean.](fphar-11-00026-g003){#f3}

Proportion of Patients in the Different Efavirenz Therapeutic Range {#s3_5}
-------------------------------------------------------------------

Previous studies have suggested that plasma efavirenz concentration below 1 and above 4 µg/ml predict treatment failure and central nervous toxicity respectively ([@B27]). Comparison of the proportion of patients in the different plasma efavirenz therapeutic ranges (\< 1, 1--4, and \> 4 µg/ml) at week 4 and week 16 among patients treated with efavirenz-based cART without (EFV only) or with rifampicin based anti-TB (EFV + RIF) stratified by country is presented in [**Table 3**](#T3){ref-type="table"}. In EFV only group, the proportion of patients having plasma efavirenz concentration below the proposed therapeutic range (\<1 µg/ml) was two-fold higher in Ethiopians than in Tanzanian counterparts, while proportion of patients having plasma concentration above the therapeutic range (\>4 µg/ml) was three-fold higher in Tanzanians than Ethiopians. In contrast, no country-specific difference in the proportion of patients in the different therapeutic ranges was observed among TB-HIV cohort co-treated with rifampicin based anti-tuberculosis therapy. Nearly a third of the patients (31%) had sub-therapeutic efavirenz plasma concentrations, with only 53% being within the recommended therapeutic range at weeks 4 or 16 after cART initiation.

###### 

The proportion of patients in the various plasma efavirenz concentration therapeutic range stratified by country and treatment group.

  Treatment group   **Country**   **Week 4 of cART**   **Week 16 of cART**                                         
  ----------------- ------------- -------------------- --------------------- ---- --------- -------- -------- ---- --------
  **EFV only**      Ethiopia      74                   129                   12   \<0.001   62       120      9    0.0005
                    34.42%        60.00%               5.58%                      32.46%    62.83%   4.71%         
                    Tanzania      32                   120                   53             26       87       21   
                    15.61%        58.54%               25.85%                     19.40%    64.93%   15.67%        
  **EFV + RIF**     Ethiopia      20                   39                    12   0.89      21       26       9    0.91
                    28.17%        54.93%               16.90%                     37.50%    46.43%   16.07%        
                    Tanzania      34                   71                    18             29       41       15   
                    27.64%        57.72%               14.63%                     34.12%    48.24%   17.65%        

Factors Influencing Plasma Efavirenz Concentration on and Off Rifampicin Co-Treatment {#s3_6}
-------------------------------------------------------------------------------------

Predictors of efavirenz plasma concentration in HIV patients without TB coinfection is presented previously ([@B37]). In brief geographic differences (patient country), *CYP2B6\*6* and *ABCB1 c.4036A/G (rs3842)* genotypes were significant predictors of efavirenz plasma concentrations.

Predictors of plasma efavirenz concentrations in TB-HIV patients co-treated with rifampicin based anti-TB therapy is presented in [**Table 4**](#T4){ref-type="table"}. Country was not associated with efavirenz concentrations at 4 or 16 weeks (p-values \> 0.05). In the multivariate model at 16 weeks of cART, there was some indication that males had lower efavirenz concentrations (mean difference log efavirenz: −0.24; 95% CI: −0.49--0.02; *p* = 0.07), but results did not reach statistical significance. *CYP2B6* genotype was a significant predictor of efavirenz concentrations at both 4 and 16 weeks. In the longitudinal model, patients with *CYP2B6\*6/\*6* and *\*1/\*6* alleles had 1.38 (95% CI: 0.98--1.78) and 0.52 (95% CI: 0.28--0.77) greater log efavirenz plasma concentrations than patients who had *CYP2B6 \*1/\*1* genotype. Predictors for efavirenz plasma concentrations below the therapeutic window threshold (\<1 µg/ml) were also assessed. Statistically significant differences were seen in the *CYP2B6* genotype distribution and efavirenz levels where 71% of the patients with \<1 µg/ml were *CYP2B6 \*1/\*1* and 48% of patients with supra-therapeutic efavirenz concentrations (\> 4 µg/ml) were *\*6/\*6* (*p* \< 0.001). Multivariate analysis showed that patients with *CYP2B6 \*1/\*6* and *\*6\*6* genotype had 0.50 (95% CI: 0.29--0.87) and 0.23 (95% CI: 0.05--1.03) times the risk of having efavirenz concentrations \<1 µg/ml as compared to those with *\*1/\*1* genotype respectively ([**Table 4**](#T4){ref-type="table"}). A total of 44% of the patients had both the *CYP2B6 \*1/\*1* and *no CYP3A5\*1* allele, and these patients had a 2.20 (95% CI: 1.25--3.82) times higher risk of having efavirenz concentrations \<1 µg/ml compared to those who did not have both alleles.

###### 

Univariate and multivariate regression analysis of plasma efavirenz concentration at 4 weeks and 16 weeks of cART during rifampicin based anti-TB co-treatment.

  Variable                           Week 4                Week 16   Longitudinal GEE analysis of 4 and 16 weeks                                                                                                                                   
  ---------------------------------- --------------------- --------- --------------------------------------------- --------- --------------------- --------- --------------------- --------- --------------------- --------- --------------------- ---------
  **Country**                                                                                                                                                                                                                                      
  Tanzania                           Ref                             Ref                                                     Ref                                                             Ref                             Ref                   
  Ethiopia                           0.01 (−0.09--0.12)    0.79      −0.00 (−0.12--0.11)                           0.98      0.01 (−0.12--0.14)    0.88      0.01 (−0.12--0.14)    0.92      0.03 (−0.07--0.13)    0.56      0.05 (−0.07--0.17)    0.45
  **Sex**                                                                                                                                                                                                                                          
  Females                            Ref                             Ref                                                     Ref                                                             Ref                             Ref                   
  Males                              −0.09 (−0.19--0.01)   0.07      −0.03 (−0.12--0.05)                           0.43      −0.16 (−0.28--0.03)   0.013     −0.10 (−0.21--0.01)   0.07      −0.10 (−0.19--0.00)   0.046     −0.06 (−0.15--0.03)   0.17
  **Type of TB**                                                                                                                                                                                                                                   
  Smear positive                     Ref                             Ref                                                     Ref                                                             Ref                             Ref                   
  Smear negative                     0.07 (−0.03--0.17)    0.18      0.05 (−0.04--0.15)                            0.27      −0.00 (−0.13--0.13)   0.97                                      0.08 (−0.02--0.18)    0.12      0.06 (−0.04--0.16)    0.21
  **WHO stage**                                                                                                                                                                                                                                    
  Stage III                          Ref                                                                                     Ref                                                             Ref                                                   
  Stage IV                           0.01 (−0.12--0.13)    0.90                                                              0.02 (−0.12--0.18)    0.77                                      0.02 (−0.11--0.14)    0.76                            
  **HAART initiated**                                                                                                                                                                                                                              
  Stavudine                          Ref                                                                                     Ref                                                             Ref                                                   
  Zidovudine                         −0.02 (−0.12--0.09)   0.77                                                              −0.05 (−0.18--0.09)   0.49                                      −0.06 (−0.16--0.04)   0.27                            
  Tenofovir                          0.12 (−0.09--0.33)    0.28                                                              0.12 (−0.17--0.40)    0.41                                      0.07 (−0.15--0.28)    0.54                            
  **BMI (kg/m^2^)**                  0.00 (−0.01--0.02)    0.57                                                              −0.00 (−0.02--0.02)   0.99                                      0.00 (−0.01--0.02)    0.94                            
  **Anemia**                                                                                                                                                                                                                                       
  ≥8.5g/dl                           Ref                                                                                     Ref                                                             Ref                                                   
  \<8.5g/dl                          0.01 (−0.13--0.15)    0.86                                                              −0.04 (−0.21--0.13)   0.65                                      0.04 (−0.09--0.18)    0.53                            
  **Hepatitis B**                                                                                                                                                                                                                                  
  Negative                           Ref                                                                                     Ref                                                             Ref                                                   
  Positive                           −0.03 (−0.29--0.23)   0.81                                                              0.19 (−0.09--0.48)    0.18      0.18 (−0.06--0.42)    0.13      0.12 (−0.12--0.36)    0.33                            
  **Hepatitis C**                                                                                                                                                                                                                                  
  Negative                           Ref                                                                                     Ref                                                             Ref                                                   
  Positive                           0.17 (−0.23--0.58)    0.40                                                              0.11 (−0.67--0.88)    0.78                                      0.22 (−0.21--0.66)    0.32                            
  **CD4 cell count**)                                                                                                                                                                                                                              
  \<100 cells/µl                     Ref                             Ref                                                     Ref                                                             Ref                             Ref                   
  ≥100 cells/µl                      0.11 (0.01--0.20)     0.037     0.08 (−0.00--0.17)                            0.050     0.06 (−0.07--0.19)    0.34                                      0.09 (0.01--0.19)     0.07      0.08 (−0.01--0.17)    0.06
  **VL log copies/ml**               −0.00 (−0.04--0.03)   0.89                                                              0.01 (−0.03--0.05)    0.64                                      −0.00 (−0.03--0.03)   0.97                            
  ***CYP2B6***                                                                                                                                                                                                                                     
  *\*1/\*1*                          Ref                             Ref                                                     Ref                                                             Ref                             Ref                   
  *\*1/\*6*                          0.17 (0.08--0.27)     0.001     0.16 (0.06--0.26)                             0.002     0.22 (0.10--0.35)     \<0.001   0.22 (0.09--0.35)     0.001     0.25 (0.15--0.36)     \<0.001   0.23 (0.12--0.33)     \<0.001
  *\*6/\*6*                          0.70 (0.54--0.86)     \<0.001   0.68 (0.51--0.84)                             \<0.001   0.71 (0.49--0.93)     \<0.001   0.68 (0.46--0.91)     \<0.001   0.63 (0.46--0.81)     \<0.001   0.59 (0.42--0.77)     \<0.001
  **Number of *CYP3A5\*1* allele**                                                                                                                                                                                                                 
  Zero                               Ref                             Ref                                                     Ref                                                             Ref                             Ref                   
  one                                0.05 (−0.08--0.18)    0.46      −0.01 (−0.12--0.10)                           0.88      −0.01 (−0.17--0.16)   0.93                                      0.08 (−0.05--0.20)    0.22      0.04 (−0.07--0.15)    0.49
  Two                                0.10 (−0.05--0.25)    0.18      0.02 (−0.13--0.16)                            0.83      0.09 (−0.09--0.29)    0.31                                      0.17 (0.03--0.31)     0.021     0.10 (−0.04--0.25)    0.15
  ***ABCB1 c 3435 C/T***                                                                                                                                                                                                                           
  CC                                 Ref                                                                                     Ref                                                             Ref                                                   
  CT&TT                              0.04 (−0.08--0.17)    0.51                                                              −0.01 (−0.17--0.15)   0.91                                      −0.00 (−0.13--0.12)   0.97                            
  ***SLCO1B1 A174V***                                                                                                                                                                                                                              
  TT                                 Ref                                                                                     Ref                                                             Ref                                                   
  CT&CC                              0.04 (−0.09--0.18)    0.56                                                              −0.12 (−0.29--0.06)   0.19      −0.03 (−0.19--0.13)   0.67      −0.02 (−0.16--0.12)   0.81                            
  ***UGT2B7***                                                                                                                                                                                                                                     
  AA                                 Ref                                                                                     Ref                                                             Ref                                                   
  AG&GG                              0.02 (−0.14--0.17)    0.81                                                              0.02 (−0.16--0.21)    0.79                                      0.03 (−0.13--0.18)    0.73                            

cART, combination antiretroviral therapy; GEE, generalized estimating equation; WHO stage, World Health Organization clinical staging; BMI, body mass index.

Predictors of Immunological Outcomes During Rifampicin Co-Treatment {#s3_7}
-------------------------------------------------------------------

Comparison of the median and interquartile range (IQR) of CD~4~ cell count at baseline, 12^th^, 24^th^, and 48^th^ week of cART between Ethiopians and Tanzanians stratified by treatment group are presented in [**Figure 4**](#f4){ref-type="fig"}. Among HIV only cohort treated with EFV based cART only, the median CD~4~ cell count was significantly higher in Tanzanians than Ethiopians at week 24 (p = 0.01) and week 48 (p = 0.001) of cART (p \< 0.001). Likewise, and the percent change of CD~4~ cell count from baseline by week-24 (p = 0.03) and 48 (p = 0.02) were higher in Tanzanian than Ethiopians.

![Comparison of change in median and interquartile range of CD4 cell count profile during combination antiretroviral-therapy (cART) among Ethiopian and Tanzanian HIV patients in the absence \[efavirenz (EFV) only\] and presence of anti-TB cotreatment \[EFV + *rifampicin* (RIF)\].](fphar-11-00026-g004){#f4}

In contrast, no significant between-country differences in median CD~4~ cell count at week 24 (p = 0.82), week 48 (p = 0.19), or percent change in CD~4~ cell count from baseline by week 24 or 48 of cART was observed among TB-HIV patients co-treated with rifampicin based anti-tuberculosis. Though not significant the CD~4~ cell-count remained consistently higher in Tanzanians than Ethiopians ([**Figure 4**](#f4){ref-type="fig"}). There was a gradual mean increase in the CD~4~ cell count from 98 (±63) cells/µl at baseline, to 231 cells/µl at 24 weeks, and 271 cells/µl at 48 weeks after cART initiation. Tanzanian patients had an overall higher median CD~4~ cell count compared to Ethiopians at week 24 (207 *vs*. 200 cells/µl) (*p =* 0.38) and at week 48 post cART (271 *vs*. 241 cells/µl) (*p =* 0.057). At the 48 weeks of cART, twice as many Ethiopians compared to Tanzanians had CD~4~ cell counts below 200 cells/µl (66% *vs*. 34% respectively).

Predictors of CD~4~ cell count by week 48 is presented in [**Table 5**](#T5){ref-type="table"}. Among TB-HIV patients, baseline BMI, viral load, and WHO clinical stage but not genotype, population variation, or plasma efavirenz concentration were significant predictors of the immunologic outcome by week 48.

###### 

Univariate and multivariate correlates of CD4 percent change from baseline to 48 weeks of cART treatment among TB-HIV coinfected patients.

  Variable                                       Univariate analysis     Multivariate analysis                              
  ---------------------------------------------- ----------------------- ----------------------- -------------------------- -------
  **Country**                                                                                                               
  Tanzania                                       Ref                                             Ref                        
  Ethiopia                                       1.72 (−48.9--52.3)      0.95                    1.5 (−60.8--63.9)          0.96
  **Sex**                                                                                                                   
  Female                                         Ref                                             Ref                        
  Male                                           −24.2 (−73.4--25.1)     0.33                    −28.6 (−75.6--18.4)        0.23
  **Type of TB**                                                                                                            
  Smear positive                                 Ref                                                                        
  Smear negative                                 35.9 (−14.9--86.8)      0.17                    60.8 (−0.26--122.0)        0.051
  **WHO stage**                                                                                                             
  Stage III                                      Ref                                             Ref                        
  Stage IV                                       −60.4 (−117.2--3.59)    0.037                   −101.0 (−161.6 -- −40.5)   0.001
  **cART initiated**                                                                                                        
  Stavudine                                      Ref                                                                        
  Zidovudine                                     −21.2 (−77.5--35.0)     0.46                                               
  Tenofovir                                      −5.65 (−76.1--64.8)     0.87                                               
  **BMI (kg/m^2^)**                              −8.3 (−16.2--0.42)      0.039                   −9.4 (−17.1 -- −1.7)       0.017
  **Anemia**                                                                                                                
  ≥8.5 g/dl                                      Ref                                             Ref                        
  \<8.5 g/dl                                     99.4 (29.1--169.6)      0.006                   60.7 (−10.8--132.2)        0.09
  **Hepatitis B**                                                                                                           
  Negative                                       Ref                                             Ref                        
  Positive                                       −99.5 (−220.1--21.2)    0.11                    −98.7 (−212.4--14.9)       0.09
  **Hepatitis C**                                                                                                           
  Negative                                       Ref                                                                        
  Positive                                       −30.0 (−284.5--224.5)   0.82                                               
  **Log viral load copies/ml**                   17.7 (2.5--32.9)        0.023                   15.0 (0.67--29.4)          0.040
  ***CYP2B6***                                                                                                              
  *\*1/\*1*                                      Ref                                                                        
  *\*1/\*6*                                      6.9 (−51.2--65.1)       0.81                                               
  *\*6/\*6*                                      −50.8 (−147.6--45.9)    0.30                                               
  **Number of *CYP3A5\*1* allele**                                                                                          
  Zero                                           Ref                                                                        
  One                                            −18.2 (−78.3--41.9)     0.55                                               
  Two                                            −13.0 (−98.4--72.3)     0.76                                               
  ***ABCB1 c 3435 C/T***                                                                                                    
  CC                                             Ref                                                                        
  CT&TT                                          −20.0 (−79.8--39.7)     0.51                                               
  ***SLCO1B1 A174V***                                                                                                       
  TT                                             Ref                                                                        
  CT&CC                                          −24.9 (−84.1--34.2)     0.41                                               
  ***UGT2B7*** (g.−327G \> A)                                                                                               
  AA                                             Ref                                                                        
  AG&GG                                          −31.3 (−101.3--38.8)    0.38                                               
  Log plasma efavirenz conc at week 4 of cART    7.8 (−75.9--91.6)       0.85                                               
  Log plasma efavirenz conc at week 16 of cART   −32.0 (−123.1--59.0)    0.49                                               

Discussion {#s4}
==========

In the present study we performed a parallel comparative multicenter prospective observational study to assess the importance of population, geographic, and pharmacogenetic variations for efavirenz pharmacokinetics and immunological outcome during antituberculosis cotreatment in two genetically different east African populations, Ethiopians, and Tanzanians. HIV patients without tuberculosis co-infection were enrolled as a control group to investigate the impact of population and geographic differences in the absence of anti-TB co-medication. Our result indicates different efavirenz plasma exposure and immunologic outcome profiles between Ethiopians and Tanzanian HIV patients depending on the presence or absence of antituberculosis co-medication. Tanzanian HIV patients treated with efavirenz-based cART only had significantly higher plasma efavirenz concentration and immunologic recovery than Ethiopian counterparts. However, this difference became insignificant during rifampicin based anti-TB co-medication. While the impact of *CYP2B6* genotype for efavirenz plasma exposure was prominent regardless of population variation or rifampicin co-medication, the importance of population variation was prominent only when efavirenz-based cART was given alone. This may indicate that findings during rifampicin based anti-TB co-treatment could possibly be extrapolated between black African populations, but not when efavirenz-based cART is given alone. To the best of our knowledge, this is the first parallel prospective study to explore the importance of between population variation for antiretroviral and antituberculosis drug interaction and its impact on efavirenz pharmacokinetics, auto-induction, and immunologic outcome in two genetically different sub-Saharan Africa population.

Change in plasma efavirenz concentration was determined at two different time points to investigate the short and long-term efavirenz auto-induction in the presence or absence of rifampicin co-treatment. Efavirenz induces its own metabolism *via* CYP2B6 and CYP3A4/5 enzymes ([@B36]: [@B18]). Our result indicates that the extent of efavirenz auto-induction is influenced by population differences, *CYP2B*6 genotype, and anti-tuberculosis co-treatment. Interestingly in the absence of anti-TB medication, efavirenz plasma concentration significantly reduced overtime particularly in Tanzanians than Ethiopians ([**Figure 3**](#f3){ref-type="fig"}). The impact of rifampicin cotreatment in reducing efavirenz plasma concentration was prominent in *CYP2B6\*1/\*1* genotype but not in *CYP2B6\*6* carriers, as revealed by a significant decline in efavirenz plasma concentration at week 4 of cART in Tanzanian *CYP2B6\*1/\*1* genotype ([**Figure 2**](#f2){ref-type="fig"}). This may indicate genotype-based preferential enzyme induction of the *CYP2B6* wild-type allele, or *CYP2B6\*6* could equally be induced, but since it codes for reduced enzyme activity no significant impact on plasma efavirenz concentration could be observed among Tanzanian patients. Interestingly, though not significant the opposite trend was observed in Ethiopian HIV patients, i.e., a trend of having higher plasma efavirenz concentration during rifampicin based anti-TB cotreatment particularly in *CYP2B6\*6* carriers.

CYP2B6, the major efavirenz metabolizing enzyme, is inducible by both efavirenz and rifampicin, and concomitant administration of the two drugs may result in additive effect to increase efavirenz clearance and reduce efavirenz plasma concentration. Indeed, studies in the white population reported that rifampicin co-treatment significantly reduced efavirenz plasma concentration ([@B24]). However, in both Ethiopians and Tanzanians TB-HIV patients, rifampicin co-treatment did not reduce efavirenz plasma concentration ([**Figure 1**](#f1){ref-type="fig"}). Similar to our finding previous studies from other black and Asian populations reported no effect or paradoxically increased plasma efavirenz concentration during concomitant rifampicin based anti-TB therapy ([@B7]: [@B16]: [@B31]: [@B32]: [@B10]). This inconsistent finding of antiretroviral-antituberculosis drug interaction between white and black populations indicates the relevance of population differences in drug-interaction studies and the need for cautious extrapolation of finding from one population to another. Our result indicates that anti-TB co-medication reduced efavirenz clearance as shown by a trend of increased plasma efavirenz concentration overtime in both study populations. A similar finding in Ugandans and other population was reported ([@B16]: [@B31]: [@B32]). Again, here *CYP2B6* genotype plays a significant role in antiretroviral-anti TB drug interactions. The increase in efavirenz plasma concentration was pronounced in those homozygous for the defective allele *CYP2B6\*6/\*6* ([**Figure 2**](#f2){ref-type="fig"}). Our finding is in line with previous reports where paradoxically elevated plasma efavirenz concentration by rifampicin co-treatment particularly in those with *CYP2B6\*6/\*6* genotype than those subjects with the same genotype but not receiving anti-tuberculous therapy ([@B23]).

In comparison to the TB-HIV patients, the HIV-only patients had higher mean efavirenz concentrations with statistically significant differences between the populations, where Tanzanian patients had much higher efavirenz concentrations compared to Ethiopian counterparts at both 4 and 16 weeks post-cART initiation ([@B37]). In the absence of rifampicin treatment, population differences plays a significant role in efavirenz pharmacokinetics, but its role diminishes in the presence of rifampicin co-treatment. Even among the rapid metabolizer groups with *CYP2B6\*1/\*1* genotypes, plasma efavirenz concentration was higher in the TB-HIV patients compared to HIV only patients. This could be explained in part by drug interactions modified by other anti-tubercular agents such as isoniazid involving other metabolizing enzymes such *CYP2A6* and N-acetyl transferase type 2 (NAT2) as suggested previously ([@B5]: [@B8]: [@B25]). These data suggest that the inducing effect of rifampicin is counterbalanced by a concentration-dependent inhibitory effect of isoniazid on efavirenz clearance. Efavirenz metabolism *via* CYP2A6 is relevant particularly in those with slow CYP2B6 enzyme activity. CYP2B6 slow metabolizers and slow-acetylation NAT2 phenotype result in lowest efavirenz apparent clearance ([@B5]: [@B25]). Isoniazid, a known inhibitor of CYP2A6, is metabolized by N-acetyltransferase-2 (NAT-2). Both CYP2A6 and NAT-2 are genetically polymorphic enzymes displaying wide between population variation in their enzyme activity ([@B13]: [@B14]). Apart from genetic factors, CYP2A6 and NAT-2 enzyme activities are also influenced by environmental factors ([@B38]: [@B4]). Hence genetic variation in CYP2A6 and NAT-2 may play a role in antiretroviral-anti-TB drug interactions by modulating plasma concentration of the inhibitor, isoniazid.

Regardless of population differences or anti-TB co-treatment, our result indicated no significant association of *CYP2B6* genotype or efavirenz plasma concentration with immunologic outcomes. Our finding is in line with previous studies that reported no association between plasma efavirenz concentration and virologic outcome ([@B11]: [@B34]). Lack of association between efavirenz plasma concentration and CD~4~ recovery or virologic decay may indicate that plasma efavirenz concentration at 600 mg daily dose is way above the threshold for virologic failure ([@B33]: [@B34]).

Multiple factors play a role in the pharmacokinetic variability of efavirenz including population variation. This study has shown differences in allele frequencies between Tanzanians and Ethiopians, and these differences may contribute to the pharmacokinetic variability when patients are treated with efavirenz and rifampicin among TB-HIV co-infected patients and more so in a similar population on efavirenz-based cART alone. This re-affirms that between population variations in drug exposures often occur, which leads to variations in clinical outcomes between different populations. Thus, knowing genetic variations in a genetically and culturally diverse African population is vital to optimizing treatment response.

The study has some limitations as we have not genotyped for other *CYP2B6* defective variant alleles such as *c.785A \> G* and *CYP2B6\*18 (c.983T \> C)* that influence efavirenz pharmacokinetics ([@B10]). In this study, we genotyped for *c.516 G \> T,* the most common *CYP2B6* defective variant SNP in the black African population. *c.516 G \> T* is in strong linkage disequilibrium with other *CYP2B6* variant alleles, including c.*785A \> G* ([@B30]). Hence *c.516 G \> T* can serve as *CYP2B6\*6* allele identifying SNP, a tag SNP for other relatively rare haplotypes, and to define clinically relevant inter-individual variability in CYP2B6 activity. Nevertheless, *CYP2B6\*18* (*c.983T \> C*) is absent in Ethiopians ([@B19]), but it is present in Tanzanians with 9.3% allele frequency ([@B26]: [@B35]). Thus, a lack of genotyping for *CYP2B6 c.983T \> C* among Tanzanians is our study limitation.

Conclusion {#s5}
==========

We report the importance of pharmacogenetic and population variation for efavirenz pharmacokinetics, auto-induction, immunologic outcome, and interaction between antiretroviral anti-tuberculosis drugs. The extent of efavirenz auto-induction over time, plasma exposure, and immunologic outcome vary between populations, partly due to *CYP2B6* genotype and antituberculosis cotreatment. *CYP2B6* genotype is the primary determinant of plasma efavirenz concentrations regardless of population and anti-TB co-medication. Population differences plays a significant role in determining efavirenz plasma concentration and immunologic outcomes particularly in the absence of anti-TB cotreatment, but not during concomitant anti-TB treatment. Our findings underscore the importance of population variations and environment factors in addition to pharmacogenetic variation for efavirenz pharmacokinetics and dose optimization strategy in sub Sharan African population.
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